Nu Holdings Ltd vs Vaxcyte Inc. Common Stock — how do they compare? Nu Holdings Ltd trades at $14.72 (market cap $75.26B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Nu Holdings Ltd is far larger — about 7.2× Vaxcyte Inc. Common Stock's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nu Holdings Ltd for 53 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| NU | PCVX | |
|---|---|---|
Market Cap | $75.26B | $10.51B |
Volume | 60,119,584 | 2,644,694 |
Sector | Financials | Health |
52-Week High | $18.76 | $73.82 |
52-Week Low | $11.60 | $40.32 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $97.88B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
NU stock trades at $14.93, down 6.75% over 24 hours amid recent volatility. The technical outlook is bullish based on moving averages, though the 6-day RSI at 88.3 suggests overbought conditions. Fundamentally, the company shows strong growth with revenue rising from $3.0B in 2022 to $10.63B in 2025 and net income margin improving to 26.99%. Recent news includes denial of Monzo acquisition talks, causing price swings.
The outlook remains positive given robust fundamentals and analyst consensus, but risks include high valuation multiples, credit concentration, and acquisition speculation volatility. Upside to the $16.53 price target offers potential, though investor caution is warranted near technical resistance.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →